Biomedical R&D company
CSPC, founded in June, 1992 and headquartered in Shijiazhuang, is a biopharmaceutical developer. The founder is Cai Dongchen. Listed on the HKEX on June 21, 1994, the company's major shareholders are Massive Top. Limited. Rivals that have direct and indirect competition with CSPC include 111 Group, JD health, Glaxo Smith Kline, Pfizer, etc.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
ResearchHealthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100